Disparities in the Availability and Acceptance of Nirsevimab in Massachusetts
Authors:
Open Access
- 4 June 2024
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 154 (1)
Abstract
Respiratory syncytial virus (RSV) causes significant respiratory illnesses in young children, with 3.2 million hospitalizations and 59 600 deaths globallyKeywords
This publication has 8 references indexed in Scilit:
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023MMWR. Morbidity and Mortality Weekly Report, 2023
- Influenza Vaccinations Among Privately and Publicly Insured Children With AsthmaAcademic Pediatrics, 2023
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term InfantsNew England Journal of Medicine, 2022
- Racial disparities in vaccination for seasonal influenza in early childhoodPublic Health, 2018
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling studyThe Lancet, 2017
- Predictors of influenza vaccination in the U.S. among children 9–13 years of ageVaccine, 2017
- Pediatric Medical Complexity Algorithm: A New Method to Stratify Children by Medical ComplexityPediatrics, 2014
- Insurance Status and Vaccination Coverage Among US Preschool ChildrenPediatrics, 2004